D.V. Babaskin, T.M. Litvinova, L.I. Babaskina, О.V. Krylova, E.A. Winter
D.V. Babaskin*, T.M. Litvinova, L.I. Babaskina, О.V. Krylova, E.A. Winter
Sechenov First Moscow State Medical University, 8-2 Trubetskaya St., Moscow, 119991, Russian Federation.
Volume - 15,
Issue - 1,
Year - 2022
To solve the problem of monitoring and supporting the drug adherence of patients with diabetes using diabetes mobile applications, expanding and developing the mobile apps market, and increasing their competitiveness, it is necessary to conduct market research of consumer preferences and competitive advantages of diabetes apps. This paper aims to analyze popular diabetes mobile applications in Russia and the possibilities of their use to monitor and support the drug adherence of patients with type 1 and 2 diabetes mellitus. Materials and methods. The object of the study was 25 diabetes apps. The survey involved 985 mobile application users from 32 regions of Russia. All respondents were divided into two target segments. The first segment (S1) included 572 patients with type 1 diabetes mellitus, while the second target segment (S2) consisted of 413 patients with type 2 diabetes mellitus. Field research was carried out by the method of oral survey (12.6%) and web survey (87.4%) using a structured questionnaire. Positioning was carried out using a qualitative method with a two-dimensional map of perception. Competitiveness was assessed by 28 experts using the quantitative method of individual scores with the calculation of integral indicators. Results and discussion. It was found that only about 50% of respondents in the target segment S2 and more than 70% in segment S1 had a high degree of drug adherence. The main barriers to the use of diabetes mobile applications were the insufficient formation of the support system for drug administration regimens (76.6%, S1 and 84.3%, S2) and technical difficulties (51.6%, S1 and 48.7%, S2). A comparative analysis of the results of positioning and assessment of competitiveness showed that some diabetes apps had a higher competitive advantage with an emphasis on supporting drug adherence compared to consumer preferences for their use. A strategic mechanism has been proposed to increase the importance of mobile applications to support drug administration, dosing, and control regimens in patients with diabetes mellitus to satisfy consumer preferences better. Conclusion. The results obtained provide a basis for the development of a set of measures for the further development of the basic segment of the diabetes mobile applications market for monitoring and supporting drug adherence and increasing the competitive advantages of mobile applications, which will contribute to the effective treatment and prevention of diabetes mellitus in Russia and globally.
Cite this article:
D.V. Babaskin, T.M. Litvinova, L.I. Babaskina, О.V. Krylova, E.A. Winter. Popular Diabetes Mobile Applications for Medication Intake Monitoring. Research Journal of Pharmacy and Technology. 2022; 15(1):347-6. doi: 10.52711/0974-360X.2022.00057
D.V. Babaskin, T.M. Litvinova, L.I. Babaskina, О.V. Krylova, E.A. Winter. Popular Diabetes Mobile Applications for Medication Intake Monitoring. Research Journal of Pharmacy and Technology. 2022; 15(1):347-6. doi: 10.52711/0974-360X.2022.00057 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2022-15-1-57
1. Patil PA, Jain RS. Theoretical Study and treatment of Novel COVID-19. Res. J. Pharmacology and Pharmacodynamics. 2020; 12(2): 71-72. https://doi.org/10.5958/2321-5836.2020.00014.2
2. Kumar R, Chawla A, Gaganpreet, Diksha. A Valuable insight to the novel deadly COVID-19: A Review. Res. J. Pharmacology and Pharmacodynamics. 2020; 12(3): 111-116. https://doi.org/ 10.5958/2321-5836.2020.00021.X
3. Kishor RS, Ramhari BM. Introduction to Covid-19. Research J. Science and Tech. 2020; 12(4): 338-345. https://doi.org/10.5958/ 2349-2988.2020.00051.0
4. Mor S, Saini P, Wangnoo SK, Bawa T. Worldwide spread of COVID-19 Pandemic and risk factors among Co-morbid conditions especially Diabetes Mellitus in India. Research J. Pharm. and Tech. 2020; 13(5): 2530-2532. https://doi.org/ 10.5958/0974-360X.2020.00450.3
5. Panchal I, Panigrahi B, Patel CN. Recent Advancement towards Treatment of Diabetes. Research J. Pharmacology and Pharmacodynamics. 2010; 2(1): 12-22.
6. Bhanushali SM, Modh KM, Anand IS, Patel CN, Dave JB. Novel Approaches for Diabetes Mellitus: A Review. Research J. Pharmacology and Pharmacodynamics. 2010; 2(2): 141-147.
7. Sujatha Kumari M, Kiran Babu M, Rehana Sulthana Md, Srinivas M, Prasanthi Ch. Diabetes Mellitus: Present status and Drug therapy Updates. Research J. Pharm. and Tech. 2014; 7(1): 84-94.
8. Panari H, Vegunarani M. Study on Complications of Diabetes Mellitus among the Diabetic Patients. Asian J. Nur. Edu. and Research. 2016; 6(2): 171-182. https://doi.org/10.5958/2349-2996.2016.00032.X
9. Abinaya SK, Vijey Aanandhi M. An Improvement in Patient Compliance in Diabetes Mellitus. Research J. Pharm. and Tech. 2018; 11(2): 587-592. https://doi.org/10.5958/0974-360X.2018.00108.7
10. Preethikaa S, Brundha MP. Awareness of Diabetes Mellitus among General Population. Research J. Pharm. and Tech. 2018; 11(5): 1825-1829. https://doi.org/10.5958/0974-360X.2018.00339.6
11. World Health Organization. Diabetes: Global report on diabetes. 2018. Available at: https://apps.who.int/iris/bitstream/handle/ 10665/275388/9789244565254-rus.pdf?ua=1(accessed on December 24, 2020).
12. IDF Diabetes atlas. 9th edition. 2019. Available at: https:// diabetesatlas.org/en/sections/worldwide-toll-of-diabetes.html (accessed on December 24, 2020).
13. Federalnyi registr bolnykh sakharnym diabetom [Federal register of patients with diabetes mellitus]. Available at: http:// sd.diaregistry.ru/ (accessed on December 24, 2020).
14. Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MA, Dedov II. Diabetes epidemiology in Russia: what has changed over the decade? Therapeutic Archive. 2019; 91(10): 4–13. https:// doi.org/10.26442/00403660.2019.10.000364
15. Dedov I, Shestakova M, Benedetti MM, Simon D, Pakhomov I, Galstyan G. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Research and Clinical Practice. 2016; 115: 90-95. https://doi.org/10.1016/ j.diabres.2016.02.010
16. Avogaro A, Fadini GP. Microvascular complications in diabetes: A growing concern for cardiologists. International Journal of Cardiology. 2019; 291: 29-35. https://doi.org/10.1016/ j.ijcard.2019.02.030
17. Alwin Robert A, Al Dawish MA. Microvascular complications among patients with diabetes: An emerging health problem in Saudi Arabia. Diabets and Vascular Disease Research. 2019; 16(3): 227-235. https://doi.org/10.1177/1479164118820714
18. Viigimaa M, Sachinidis A, Toumpourleka M, Koutsampasopoulos K, Alliksoo S, Titma T. Macrovascular Complications of Type 2 Diabetes Mellitus. Current Vascular Pharmacology. 2020; 18(2): 110-116. https://doi.org/10.2174/1570161117666190405165151
19. Pervyi mezhdunarodnyi mezhdistsiplinarnyi sammit "Sakharnyi diabet i serdechno-sosudistye zabolevaniya" [The first international interdisciplinary summit "Diabetes mellitus and cardiovascular diseases"]. Effektivnaya farmakoterapiya. 2019; 15(25): 6-7.
20. Agarwal P, Mukerji G, Desveaux L, Ivers NM, Bhattacharyya O, Hensel JM, Shaw J, Bouck Z, Jamieson T, Onabajo N, Cooper M, Marani H, Jeffs L, Bhatia RS. Mobile App for Improved Self-Management of Type 2 Diabetes: Multicenter Pragmatic Randomized Controlled Trial. JMIR Mhealth Uhealth. 2019; 7(1): e10321. https://doi.org/10.2196/10321
21. Jeffrey B, Bagala M, Creighton A, Leavey T, Nicholls S, Wood C, Longman J, Barker J, Pit S. Mobile phone applications and their use in the self-management of Type 2 Diabetes Mellitus: a qualitative study among app users and non-app users. Diabetology and Metabolic Syndrom. 2019; 11: 84. https://doi.org/10.1186/ s13098-019-0480-4
22. Zhang Y, Li X, Luo Sh, Liu Ch, Liu F, Zhou Zh. Exploration of Users' Perspectives and Needs and Design of a Type 1 Diabetes Management Mobile App: Mixed-Methods Study. JMIR Mhealth Uhealth. 2018; 6(9): e11400. https://doi.org/10.2196/11400
23. Fleming GA, Petrie JR, Bergenstal RM, Holl RW, Peters AL, Heinemann L. Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetes Care. 2020; 43(1): 250-260. https:// doi.org/10.2337/dci19-0062
24. Rodríguez AQ, Wägner. AM Mobile phone applications for diabetes management: A systematic review. Endocrinología, Diabetes y Nutrición. 2019; 66(5): 330-337. https://doi.org/ 10.1016/j.endinu.2018.11.005
25. Shan R, Sarkar S, Martin SS. Digital health technology and mobile devices for the management of diabetes mellitus: state of the art. Diabetologia. 2019; 62(6): 877-887. https://doi.org/ 10.1007/s00125-019-4864-7
26. Wu X, Guo X, Zhang Zh. The Efficacy of Mobile Phone Apps for Lifestyle Modification in Diabetes: Systematic Review and Meta-Analysis. JMIR Mhealth Uhealth. 2019; 7(1): e12297. https:// doi.org/10.2196/12297
27. Han J, King F, Klonoff D, Drincic A, Crosby KP, Robinson T, Gabbay RA, Oley L, Ahn D, Evans B, Salber P, Cruz M, Ginsberg B, Adi S, Armstrong D, Kerr D. Digital Diabetes Congress 2019. Journal of Diabetes Science and Technology. 2019; 13(5): 979-989. https://doi.org/10.1177/1932296819872107
28. Muoio D. Report: Digital diabetes market surging, will hit $742M by 2022. September 6, 2018. Available at: https:// www.mobihealthnews.com/content/report-digital-diabetes-market-surging-will-hit-742m-2022 (accessed on December 24, 2020).
29. Briganti G, Le Moine O. Artificial Intelligence in Medicine: Today and Tomorrow. Front Med (Lausanne). 2020; 7: 27. https:// doi.org/10.3389/fmed.2020.00027
30. Dankwa-Mullan I, Rivo M, Sepulveda M, Park Y, Snowdon J, Rhee K. Transforming Diabetes Care Through Artificial Intelligence: The Future Is Here. Population Health Management. 2019; 22(3): 229-242. https://doi.org/10.1089/pop.2018.0129
31. Broome DT, Hilton CB, Mehta N. Policy Implications of Artificial Intelligence and Machine Learning in Diabetes Management. Current Diabetes Reports. 2020; 20(2): 5. https:// doi.org/10.1007/s11892-020-1287-2
32. Ellahham S. Artificial Intelligence: The Future for Diabetes Care. The American Journal of Medicine. 2020; 133(8): 895-900. https://doi.org/10.1016/j.amjmed.2020.03.033
33. Kjos AL, Vaughan AG, Bhargava A. Impact of a mobile app on medication adherence and adherence-related beliefs in patients with type 2 diabetes. Journal of the American Pharmacists Association. 2019; 59(2S): S44-S51.e3. https://doi.org/10.1016/ j.japh.2018.12.012
34. Babaskin DV, Litvinova TM, Babaskina LI. The Effect of the Phytocomplex Electrophoresis on the Clinical Symptomatology and Quality of Life of Patients with the Knee Joint Osteoarthritis. Open Access Macedonian Journal of Medical Sciences. 2019; 7(14): 2236-2241. https://doi.org/10.3889/oamjms.2019.603
35. Huang Zh, Tan E, Lum E, Sloot P, Boehm BO, Car J. A Smartphone App to Improve Medication Adherence in Patients With Type 2 Diabetes in Asia: Feasibility Randomized Controlled Trial. JMIR Mhealth Uhealth. 2019; 7(9): e14914. https://doi.org/ 10.2196/14914
36. Babaskin DV, Litvinova TM, Babaskina LI, Ovakimyan AK, Kolevatova KY. Marketing evaluation of consumer preferences in using mobile apps for healthcare to support drug adherence. Periodico Tche Quimica. 2020; 17(35): 1013-1027.
37. ICC, ESOMAR. International code on market, opinion and social research and data analytics. 2016. Available at: https:// www.esomar.org/uploads/pdf/professional-standards/ ICCESOMAR_Code_English_.pdf (accessed on December 24, 2020).
38. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care. 1986; 24: 67-74.
39. Malhotra NK. and Birks DF. Marketing Research: An Applied Orientation. Englewood Cliffs, N.J.: Prentice Hall Inc. 1999; 865 p.
40. Babaskin DV, Litvinova TM, Babaskina LI, Okonenko TI, Rumyantsev YY. Competitive Advantages of the Rehabilitation Methods under Development as a Strategic Factor of their Introduction Efficiency (Through the Example of Phytocomplex SMC-Electrophoresis). Journal of Pharmaceutical Sciences and Research. 2018; 10(5): 1292-1296. Available at: https:// www.jpsr.pharmainfo.in/Documents/Volumes/vol10Issue05/jpsr10051872.pdf (accessed on December 24, 2020).
41. Vasnetsova OA. and Babaskin DV. Medical and pharmaceutical commodity science. Moscow: Sechenov First Moscow State Medical University. 2017; 324 р.
42. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AA, Isakov MA. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of hypoglycaemic therapy according to the Federal Diabetes Register, status 2017. Diabetes Mellitus. 2018; 21(3): 144-159. https://doi.org/10.14341/DM9686
43. Shestakova MV, Dedov II. Diabetes mellitus in the Russian Federation: Arguments and facts. Therapeutic Archive. 2016; 88(10): 4-8. https://doi.org/10.17116/terarkh201688104-8
44. Department of the Federal Service for Supervision of Consumer Rights Protection and Human Wellbeing in the Tambov Region. Sakharnyi diabet v tsifrakh: deistvitelnost i prognozy [Diabetes mellitus in numbers: reality and predictions]. Available at: http://68.rospotrebnadzor.ru/content/545/21700/(accessed on December 24, 2020).
45. Zuenkova J. Market analysis of mobile APPS for remote monitoring of diabetes melitus. Marketing i logistika. 2020; 3(29): 59-76.
46. Kotler Ph. and Armstrong G. Principles of Marketing. 13th Edition. Englewood Cliffs, N.J.: Prentice Hall PTR. 2008; 744 р.
47. Martinez-Millana A, Jarones E, Fernandez-Llatas C, Hartvigsen G, Traver V. App Features for Type 1 Diabetes Support and Patient Empowerment: Systematic Literature Review and Benchmark Comparison. JMIR Mhealth Uhealth. 2018; 6(11): e12237. https://doi.org/10.2196/12237
48. Sydow L. The New Normal in 2021: Five Things You Need to Know in Mobile. November 10, 2020 Available at: https:// www.appannie.com/en/insights/market-data/2021-five-things-you-need-to-know-in-mobile/ (accessed on December 24, 2020).
49. Fernández-Caramés TM, Froiz-Míguez I, Blanco-Novoa O, Fraga-Lamas P. Enabling the Internet of Mobile Crowdsourcing Health Things: A Mobile Fog Computing, Blockchain and IoT Based Continuous Glucose Monitoring System for Diabetes Mellitus Research and Care. Sensors. 2019; 19(15): 3319. https://doi.org/ 10.3390/s19153319
50. Mobilnye prilozheniya dlya upravleniya sakharnym diabetom: Diabetes: M [Diabetes management mobile apps: Diabetes: M]. Dimson’s Blog. November 14, 2017. Available at: http:// dimson3d.blogspot.com/2017/11/diabetes-m-review-rus.html (accessed on December 24, 2020).
51. Kebede MM, Pischke CR. Popular Diabetes Apps and the Impact of Diabetes App Use on Self-Care Behaviour: A Survey Among the Digital Community of Persons With Diabetes on Social Media. Frontiers in Endocrinology. 2019; 10(135): 1-14. https:// doi.org/10.3389/fendo.2019.00135
52. Gamble A, Pham Q, Goyal Sh, Cafazzo JA. The Challenges of COVID-19 for People Living With Diabetes: Considerations for Digital Health. JMIR Diabetes. 2020; 5(2): e19581. https:// doi.org/10.2196/19581
53. Phillip M, Bergenstal RM, Close KL, Danne T, Garg S, Heinemann L, Hirsch IB, Kovatchev B, Laffel LM, Mohan V, Parkin CG, Battelino T. The Digital/Virtual Diabetes Clinic: The Future Is Now-Recommendations from an International Panel on Diabetes Digital Technologies Introduction. Diabetes Technologe and Therapeutics. 2020; 23(2): 146-154. https://doi.org/10.1089/ dia.2020.0375